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Abstract
The numerous γ-aminobutyric acid type A receptor (GABAAR) subtypes are differentially
expressed and mediate distinct functions at neuronal level. In this study we have investi-
gated GABAAR-mediated modulation of the spontaneous activity patterns of primary neuro-
nal networks from murine frontal cortex by characterizing the effects induced by a wide
selection of pharmacological tools at a plethora of activity parameters in microelectrode
array (MEA) recordings. The basic characteristics of the primary cortical neurons used in
the recordings were studied in some detail, and the expression levels of various GABAAR
subunits were investigated by western blotting and RT-qPCR. In the MEA recordings, the
pan-GABAAR agonist muscimol and the GABABR agonist baclofen were observed to medi-
ate phenotypically distinct changes in cortical network activity. Selective augmentation of
αβγGABAAR signaling by diazepam and of δ-containing GABAAR (δ-GABAAR) signaling by
DS1 produced pronounced changes in the majority of the activity parameters, both drugs
mediating similar patterns of activity changes as muscimol. The apparent importance of δ-
GABAAR signaling for network activity was largely corroborated by the effects induced by
the functionally selective δ-GABAAR agonists THIP and Thio-THIP, whereas the δ-GABAAR
selective potentiator DS2 only mediated modest effects on network activity, even when co-
applied with low THIP concentrations. Interestingly, diazepam exhibited dramatically right-
shifted concentration-response relationships at many of the activity parameters when co-
applied with a trace concentration of DS1 compared to when applied alone. In contrast, the
potencies and efficacies displayed by DS1 at the networks were not substantially altered by
the concomitant presence of diazepam. In conclusion, the holistic nature of the information
extractable from the MEA recordings offers interesting insights into the contributions of vari-
ous GABAAR subtypes/subgroups to cortical network activity and the putative functional
interplay between these receptors in these neurons.
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Introduction
γ-Aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous
system (CNS), exerts its physiological effects through two distinct receptor families, the
GABAA and GABAB receptors (GABAARs and GABABRs, respectively) [1–3]. The GABAARs
are a highly heterogenous family of ligand-gated anion-selective channels, and the abundance
of GABAergic neurons and the key roles played by GABAARs in the CNS means that the
receptors hold considerable potential as targets for therapeutic invention in a wide range of
central disorders. Thus, GABAARs are targeted by drugs used in the clinical treatment of sleep-
ing disorders, anxiety and epilepsy, and they are pursued as putative drug targets in numerous
neurodegenerative, cognitive and psychiatric disorders [4–9]. However, the widespread
expression of GABAARs and the multiple functions governed by different receptor subtypes
are also believed to be at the root of many of the adverse effects associated with the fairly non-
selective GABAAR-based therapeutics currently available. Thus, an increased understanding of
the physiological functions mediated by different GABAARs could potentially form the basis
for development of more efficient and/or safer drugs [2, 3].
The GABAAR is a pentameric membrane-bound subunit complex, and the heterogeneity of
native GABAAR populations arises from the existence of a total of 19 subunits (α1-α6, β1-β3,
γ1-γ3, δ, ε, π, θ, ρ1-ρ3) that assemble into a plethora of receptor subtypes differentially ex-
pressed throughout the CNS [2, 3]. The molecular diversity of GABAARs is also considerable
at the neuronal level. The synaptic GABAARs expressed at postsynaptic densities that mediate
“phasic inhibition” are predominantly αβγ receptors composed of α1, α2 and/or α3, β2 and/or
β3, and γ subunits (typically γ2) [2, 3]. In addition to these receptors, activation of perisynaptic
or extrasynaptic GABAARs by low levels of ambient GABA gives rise to a persistent “tonic
inhibition” that regulates the excitability and the firing mode of the neuron [10, 11]. The α4βδ
receptors constitute the major extrasynaptic GABAAR in most brain regions, in particular in
the forebrain, with α6βδ GABAARs being the predominant extrasynaptic receptors in cerebel-
lum and with α5βγ2 and α1βδ receptors being important mediators of tonic inhibition in hip-
pocampal and neocortical pyramidal cells and interneurons, respectively [2, 10–13]. These
different locations of the receptors at the neuronal body mean that they mediate different con-
tributions to synaptic transmission and neuronal activity. Both overall excitability and output
of the specific neuron and global neuronal network activity is regulated by a multitude of
mechanisms, and a component of the homeostatic plasticity of GABAergic synapses seems to
arise from yet poorly elucidated interactions between phasic and tonic inhibition [14].
The respective roles of different GABAAR subtypes in GABAergic neurotransmission have
most often been studied in electrophysiological recordings of phasic and tonic currents in cul-
tured neurons or brain slices from rodents. While these recordings provide detailed insight
into the GABAARs expressed in specific neurons and their importance for neuronal activity
and synaptic transmission, the recordings do not necessarily elucidate the overall effects of
GABAAR-mediated signaling at entire neuronal networks. The use of microelectrode arrays
(MEAs) enables the recordings of extracellular action potentials of cultured neurons and thus
elucidatation of the activity characteristics of neuronal networks. For more than 20 years, this
technological platform has been used for studying neurotoxic effects of compounds and toxins
[15–17] but also in studies investigating the functional modes of action of ligands [17–22]. In
the present study, we have applied this technology to study the effects induced by a broad
selection of pharmacological tools characterized by different GABAAR subtype-selectivity pro-
files at the spontaneous activity patterns of primary neuronal networks from murine frontal
cortex, and in this way we have elucidated GABAAR-mediated effects on neuronal activity in a
more holistic manner than possible by conventional slice and patch-clamp electrophysiology.
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Materials and methods
Drugs
THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol, also termed gaboxadol) and Thio-
THIP (4,5,6,7-tetrahydroisothiazolo[5,4-c]pyridin-3-ol) were synthesized in-house essentially
as previously described [23, 24]. DS1 (4-chloro-N-[6,8-dibromo-2-(2-thienyl)imidazo[1,2-a]
pyridine-3-yl benzamide), DS2 (4-chloro-N-[2-(2-thienyl)imidazo[1,2-a]pyridine-3-yl benza-
mide) and flunitrazepam were obtained from Sigma-Aldrich (Copenhagen, Denmark), Tocris
Cookson (Bristol, UK) and Roche (Mannheim, Germany), respectively, and diazepam, clonaz-
epam, zolpidem, muscimol and baclofen were purchased from Sigma-Aldrich (Munich, Ger-
many). The in vitro pharmacological properties of the respective drugs are given in Table 1
and will be outlined given in more detail in Results.
Ethics
All neural tissue from animal were prepared according to the EU Directive 2010/63/EU on the
protection of animals used for scientific purposes (certification file number 7221.3–2). In this
study no animal experiments were performed in accordance with the German Animal Protec-
tion §7/2 (Tierschutzgesetz). Time-pregnant animals were purchased and shipped by a
licensed animal supplier Charles River, Germany. Animals were stored in a separate room for
less than 24 hours after arrival in their transport boxes including food and water equivalent.
Animal storage is supervised by an animal welfare officer at NeuroProof GmbH, Germany.
Short-term storage of animals in transport boxes is in agreement with Directive (EG) Nr. 1/
2005 (Animal safety during transport). The mice were sacrificed by cervical dislocation
according to the German Animal Protection Act §4.
Primary cell cultures
Pre-frontal cortex tissue was harvested from embryonic day 15/16 chr:NMRI mice (Charles
River). Tissue was dissociated by enzymatic digestion (133,3 Kunitz units/ml DNase; 10
Units/ml papain) and mechanical trituration, counted, vitality controlled, and plated in
DMEM containing 5% fetal bovine serum and 5% horse serum on poly-D-lysine- and lami-
nin-coated microelectrode array (MEA) neurochips with 2x32 passive electrodes for two inde-
pendent experiments per MEA (Center for Network NeuroScience, University of North Texas,
Denton, TX). The density of plating was 4,000 cells per mm2. Cultures on the MEA chips were
Table 1. Pharmacological properties of the drugs used in the present study.
Drug Pharmacological properties
Baclofen pan-GABABR agonist
Muscimol pan-GABAAR agonist
Diazepam Benzodiazepine, PAM at α1,2,3,5βγGABAARs
Flunitrazepam Benzodiazepine, PAM at α1,2,3,5βγGABAARs
Clonazepam Benzodiazepine, PAM at α1,2,3,5βγGABAARs
Zolpidem Benzodiazepine-site modulator, PAM at α1,2,3,5βγGABAARs, exhibits potency-based
preference for α1βγGABAARs
THIP GABAAR agonist, exhibits potency-based preference for δ-containing GABAARs
Thio-THIP Functionally selective GABAAR ligand, exhibit agonism at α4β1,3δ and weak antagonism at
αβγ and α4β2δGABAARs
THIP Allosteric agonist and PAM, efficacy-based selectivity for δ-containing GABAARs
Thio-THIP PAM, efficacy-based selectivity for δ-containing GABAARs
https://doi.org/10.1371/journal.pone.0186147.t001
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incubated at 37˚C in a 10% CO2 atmosphere until ready for use, typically four weeks after seed-
ing. Culture media was replenished twice a week with DMEM containing 10% horse serum.
The developing co-cultures were treated with the mitosis inhibitor 5-fluoro-2’-deoxyuridine
(25μM) and uridine (63 μM) for 48 h on day 5 after seeding to prevent further glial prolifera-
tion. After 4 weeks in culture, the activity pattern stabilizes and is composed of one coordi-
nated main burst pattern with several coordinated sub-patterns [18, 19, 25–29]. In this study
cultures between 28 and 35 days in vitro were used.
Multichannel recordings and data analysis
Extracellular recordings were performed using a computer-controlled 64-channel MEA work-
station acquisition system (Plexon, Inc., Dallas, TX), where temperature control of 37˚C and
stable pH of 7.4 (10% CO2) enabled stable recording and cumulative concentration-response
determinations for periods longer than 10 h. Recordings were performed as previously re-
ported using a computer-controlled 64-channel MEA workstation acquisition system (Plexon,
Inc., Dallas, TX) providing amplification, filtering and digital signal processing of MEA signals
[20]. The total system gain used was 10 K with a simultaneous 40 kHz sampling rate, and the
signals routinely recorded by these neurochips are located in the range of 15–800 μV [20]. The
neuronal networks were acutely treated with a series of accumulating increasing concentra-
tions of the test compound (maximum assay concentration of DMSO: 0.1%), and the record-
ings were performed over time periodes of 8–9 h. The network response (spike rate) was
observed online. Each of the test compound concentrations was applied and incubated for at
least 60 minutes of which a stable phase of 30 minutes was used for data analysis, and real time
unit separation and spike identification were performed in real time as previously described.
The multichannel signal acquisition system delivered single neuron spike data including action
potential waveforms. Spike identification and separation were accomplished using a template-
matching algorithm in real time [20]. This permitted the simultaneous extracellular recording
of action potentials from a maximum of 256 neurons per MEA, thus 128 per experiment. The
action potentials, or “spikes”, were recorded as spike trains; they are clustered in so-called
bursts. Bursts were quantitatively described via direct spike train analysis using the program
NeuroEXplorer (Plexon Inc., Dallas, TX) and NPWaveX (NeuroProof GmbH, Rostock, Ger-
many). Bursts were defined by the beginning and end of short spike events. Maximum spike
intervals defining the start of a burst were adjusted from 50 to 150 ms, and maximum intervals
to end a burst from 100 to 300 ms [20]. Bursts definition and high content analysis of the net-
work activity patterns provided a multiparametric description characterizing the activity
changes in four defined categories: “General Activity”, “Burst Structure”, “Oscillatory Behaviour”
and “Synchronicity” (presented in detail in section 3.1.2). Unless otherwise specified, the param-
eters for each experiment and each experimental treatment were normalized to the correspond-
ing values of the native reference activity. Our minimal acceptance criteria for active MEA
networks was 6 bursting neurons in a network as this allows a network analysis using the syn-
chronicity measures. In average 25 active units (from 32 electrodes) were recorded per network,
with peaks of up to 100 units per network. The data from the recordings with DS2 (alone) has
been published previously [22], whereas the other data presented in this study has not.
In the figures in this study, heat map presentations depicting the changes induced by the
various pharmacological tools in 40 of the 204 activity parameters are given together with con-
centration-response curves for 10 selected activity parameters. The definitions of some of
these activity parameters have been presented in a recent publication [30], and the definitions
of all 40 parameters shown in the figures are given in S1 Table. In brief: spike rate: number of
spikes per second, averaged over all spike trains recorded per 60 s bin; burst rate: number of
GABAA receptor-mediated modulation of cortical network activity in microelectrode array recordings
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bursts per second, a measure for burstiness of units averaged over all units recorded per 60 s
bin; burst duration: mean lengths of bursts (in ms) based on inter-spike interval (ISI) method;
burst amplitude: bursts are mathematically superimposed with an integral function defined by
spike peak density in bursts and number of spikes, and burst amplitude is the peak amplitude
of the integrated burst reflecting the fraction of the bursts with highest spike density; spike rate
SD and burst rate SD: SD of spike and burst rate, respectively, across 60 s bins, indicating the
variability of spikiness and burstiness of units within temporal episodes; spike rate CVnet and
burst rate CVnet: coefficient of variation of spike and burst rate, respectively, reflecting spatial
variation of spike and burst rate over the network during experimental episodes; Syn All: aver-
age distance of bursts within a population burst from population burst center, a measure for
the strength of synchronicity of a network; Spike Simplex; spike trains are divided into time-
frames of 1 ms bin-size, and within these bins different units within the network generate
spikes. All units exhibiting a spike are defined as one simplex, and the outcome of the quantity
of all simplex is the “Spike Simplex”, a measure for connectivity and complexity in neuronal
network (higher values reflect higher synchronicity among neurons). Distribution of “Simplex
events” are not distributed as in an in silico-generated poisson spike train. A detailed analysis
shows that different units are involved in “Simplex events”. Doublete analyses (separation of
units with identical origin) showed that the probability of doublets is below 1%.
Statistical analysis
We used a minimum of 2 MEAs per animal preparation, and data were produced from cul-
tures of at least 3 independent animal preparations. The data is pooled over all MEAs per test
group. Concentration-response effects are shown as mean values ± SEM. Statistical analysis
includes ANOVA followed by Student’s paired t-test when compared to native activity,
unpaired t-test when compound effects are compared with each other. P values 0.05 are rep-
resented with , p 0.01 with  and p 0.001 with . Heat maps show only colored rectan-
gles if p 0.05, colors encode effect sizes as shown in the color legend. The data for the
different drugs are based on the following numbers of MEA experiments: DMSO: 12. musci-
mol: 7, baclofen: 8, diazepam: 11, clonazepam: 14, zolpidem: 12, flunitrazepam: 12, THIP: 9,
Thio-THIP: 9, DS2: 11, DS1: 10, [DS2 + 3 μM THIP]: 17, [DS2 + 15 μM THIP]: 8, [THIP
+ 300 nM DS2]: 12, [THIP + 1 μM DS2]: 11, [THIP + 3 μM DS2]: 15, [diazepam + 30 nM
DS1]: 9, [DS1 + 50 nM diazepam]: 14.
Immunocytochemistry and microscopy
Primary prefrontal cortex neurons were fixed for 20 min with phosphate-buffered saline (PBS)
containing 4% paraformaldehyd, and 4% sucrose, followed by blocking with PBS containing
40 nM NH4Cl. Membrane permeabilization was performed with PBS containing 0.1% Triton-
X100 for 5 min. Permeabilized cells were blocked using PBS contining 1% BSA, 2% goat serum
and 0.05% Tween20). Primary and secondary antibodies were incubated at room temparature
for 1 h each in a humified chamber. The following antibodies and dilutions were used: α1
GABAAR (Synaptic Systems; 1:500), synapsin-1 (New England Biolabs; 1:200), β3-tubulin
(Sigma, 1:1000), Hoechst-Bisbenzimid (Sigma Aldrich, 1 μg/ml), and secondary antibodies
(1.500; Alexa fluor 488 and 594-conjugated goat-anti-mouse and goat-anti-rabbit, Invitrogen).
Images were acquired using a Nikon Eclipse fluorescence microscope. Image analysis (synapse
isolation) was performed using ImageJ software (NIH). Images were analyzed by semi-auto-
matic image quantification tools (MS Excel macro-based in-house analyses; ImageJ, Rawak
Software, NIH, USA). The following parameters were quantified per image, means and SEM’s
were calculated afterwards: cell number: absolute number of nuclei / field (marker: nuclear
GABAA receptor-mediated modulation of cortical network activity in microelectrode array recordings
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staining, automatic counting after image processing (binary, watershed), neuronal number:
absolute number of neuronal soma / field (marker: HuC/D-positive objects, manual and semi-
automatic counting), synapse number: absolute number of synapse punctae / field (image
binarized, automatic analysis: local automatic threshold setting, watershed filter for object
separation).
Western blotting
The primary cortical cells and mouse brains were lysed using RIPA lysis buffer. SDS gel
electrophoresis was performed using 12% pre-cast Bis-Tris gels (Novex™, NuPAGE™). Immu-
noblotting was performed using iBlot System and transfer Stacks PVDF. All steps were per-
formed according to the manufaturer’s instructions. 10 μg protein was loaded per lane.
Membranes were blocked for 1 hour using WesternBreeze Blocker solution (all materials from
Invitrogen). The following primary antibodies and dilutions were used: α1 GABAAR (Synaptic
System, 1:375), α3 GABAAR (Millipore, 1:200), α5 GABAAR (Abd-Serotec, 1:200), PSD-95
(Cell Signalling, 1:1000) and SNAP-25 (Synaptic Systems, 1:5000). Two α2 GABAAR antibod-
ies were tested but were found to lack specificity. Primary antibodies were incubated over
night at 4˚C. Secondary antibodies (goat-anti-mouse, goat-anti-rabbit, both AP-conjugated,
Life Technologies) were incubated for 1 h at room temperature. AP-conjugate was incubate
for 5 min before signal acquisition using BioRad ChemiDoc XRS System and Gen5 Software
(BioRad) for band quantification. Data from at least 3 lysates were summarized for band quan-
tification. Western blot data is shown as mean values ± S.D.
RT-qPCR
Primary neurons were harvested on the same day as the MEA recordings were performed, and
cDNA derived from mouse prefrontal cortex were used as control. Total RNA was extracted
using RNA mini kit from Qiagen (Thermo Fisher Scientific, Waltham, MA) according to the
manufacturer’s protocol. The reverse transcription was performed using qScript™ cDNA
SuperMix (Quanta Biosciences, Gaithersburg, MD) on a standard PCR machine (25˚C for 5
min, 42˚C for 30 min, 85˚C for 5 min) and cDNA stored at -20˚C until further processing.
qPCR was performed essentially as previously described in 96-well plates (Agilent Technolo-
gies, Santa Clara, CA) mixing PerfeCTa SYBR Green FastMix (Quanta Biosciences), nuclease
free water (Qiagen, West Sussex, UK) and primers (TAG Copenhagen A/S (Copenhagen, Den-
mark) (Table 2) [31]. The Primer pairs were validated using a serial dilution of cDNA and only
Table 2. Sequences of primers used in the RT-qPCR.
Target Genes Primers
α4 F: 5’-AGAACTCAAAGGACGAGAAATTGT-3’
R: 5’-TTCACTTCTGTAACAGGACCCC-3’
β1 F: 5’- GGTTTGTTGTGCACACAGCTCC-3’
R: 5’- ATGCTGGCGACATCGATCCGC-3’
β2 F: 5’-GCTGGTGAGGAAATCTCGGTCCC-3’
R: 5’-CATGCGCACGGCGTACCAAA-3’
β3 F: 5’-GGGACCCCCGAAGTCGGGTCT-3’
R: 5’-GAGCGTAAACGACCCCGGGAA-3’
δ F: 5’- TCAAATCGGCTGGCCAGTTCCC-3’
R: 5’- GCACGGCTGCCTGGCTAATCC -3’
Reference gene Primers
Rpl13a F: 5’- GGAGGGGCAGGTTCTGGTAT-3’
R: 5’- TGTTGATGCCTTCACAGCGT-3’
https://doi.org/10.1371/journal.pone.0186147.t002
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primers that showed single product amplification and efficiency of 100% (± 5%) were used for
further analyses. The qPCR was performed with an initial denaturation step of 95˚C for 30 s,
followed by 40 cycles of 5 s at 95˚C, 60˚C for 15 seconds and 72˚C for 10 s. To assure single-
product amplification, a dissociation curve analysis was performed consisting of 60 s at 95˚C,
30 s at 55˚C and 30 s at 95˚C. The qPCR was performed using the Agilent Mx3005P qPCR sys-
tem (Agilent Technologies), and the corresponding MxPro software was used to determine the
Ct values. The ΔCt values were calculated using 2(Reference Ct—Target Ct) as previously described
[32].
Results
MEA recordings and multi-parametric analysis of network activity in
primary cortical neurons
In this study the effects of various pharmacological tools on network activity were character-
ized in MEA recordings at primary neurons from murine frontal cortex, and in our analysis
of these data we took advantage of the high-content information provided by multichannel
recordings. Following an outline of some basic characteristics of the primary cortical neurons
used for the recordings and of the principles of the MEA recordings and the analysis of the
data from them in this section, these results will be outlined in sections 3.2–3.6.
Basic characteristics of the primary cortical neurons. As mentioned in section 2.2, the pri-
mary neurons were used for the MEA recordings between 28 and 35 days in vitro. Due to the
serum used in the culture medium glia survival is supported in these cultures, and mainly
because of proliferation of glia during the first 4 days after plating these neuron-glia co-cul-
tures thus consist of approximately 20% neurons and 80% astrocytes including 1% microglia
[30]. This neuron/glia ratio of ~0.25 differs from the reported neuron/glia ratio of ~0.8 in
mouse frontal cortex in vivo [33]. On the other hand, we have previously determined that
approximately 20% of the neurons in these cultures are GABAergic neurons, which is in excel-
lent agreement with ratio of GABAergic neurons (relative to total number of neurons) in
mouse frontal cortex in vivo [30, 34]. In the present study, we investigated the composition of
the cortical networks and the nature and degree of synapse formation in them by means of
immunocytochemistry using antibodies targeting synapsin-1, β3-tubulin and Hoechst-Bisben-
zimid as markers for synaptic punctae, neurons and nuclei, respectively (n = 6). As can be seen
from Fig 1A, the structure and branching pattern of the neuronal networks looked comparable
to those in vivo, and image analysis (synapse isolation) of cultures stained for synapsin-1 iden-
tified a high number of synaptic punctae per neuron. Although synapsin-1 is a neuron-specific
phosphoprotein that binds selectively to vesicles in the presynaptic terminal and thus exclu-
sively is a presynaptic marker [35], this nevertheless demonstrates the formation of a plethora
of poly-synaptic connections in the cortical networks analogeously to in vivo.
Next we investigated to which extent the primary cortical neurons express the different
GABAAR subtypes. Immunocytochemistry analysis using anti-α1 antibody demonstrated
robust expression of this subunit at synaptic densities in the neurons (Fig 1B). Moreover, the
expression levels of various GABAAR subunits in the primary neurons were investigated by
western blotting and RT-qPCR analysis and compared to the expression levels of the subunits
in postnatal mouse frontal cortex tissue. As can be seen from Fig 1C, developmental changes
in expression of the α1, α3 and α5 proteins in the primary neurons at 7, 14, 21, 28 and 35 DIV
differed, with α1 subunit levels increasing during culture while both α3 and α5 expression levels
decreased over time. Importantly, these opposite trends for α1 and α3 expression levels over
time were found to be comparable to the trends determined for the two subunits in vivo in
lysates from frontal mouse cortex 7, 14, 21 and 28 days postnatally (Fig 1D), which again were
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Fig 1. Biochemical characterization of cortical network characteristics and GABAAR subunit expression in primary cortical neurons and in mouse
frontal cortex tissue. A. Immunocytochemistry characterization of the primary cortical neurons (28 DIV). i. Staining with antibodies for synapsin-1 (green),
β3-tubulin (red) and Hoechst-Bisbenzimid (blue). ii. Neurons. iii. Isolated synaptic punctae. iv. Nuclei. B. Immunocytochemistry characterization of α1
GABAAR protein expression in the primary cortical neurons (28 DIV). Staining for α1 (red), β3-tubulin (green) and Hoechst-Bisbenzimid (blue). C. Western blot
analysis of α1, α3 and α5 GABAAR protein expression levels in the primary neurons (7, 14, 21, 28 and 35 DIV). D. Western blot analysis of α1 and α3 protein
expression levels in the primary neurons (7, 14, 21 and 28 DIV) and in postnatal mouse frontal cortex (7, 14, 21 and 28 days postnatally). E. RT-qPCR
analysis of α4, β1, β2, β3 and δmRNA expression levels (± S.D.) in the primary neurons and in postnatal mouse cortex tissue (relative to the expression of the
reference gene RPL13a).
https://doi.org/10.1371/journal.pone.0186147.g001
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in good agreement with the developmental trends for the two subunits reported from studies
in rats and primates [36–39].
The expression levels of the α4 and δ GABAAR subunits in the primary neurons were also
investigated by western blot analysis, and two different commercially available antibodies were
tried for each subunit in these experiments. Despite these efforts we were unable to detect sig-
nificant and convinving bands for either of these subunits when compared with the protein
detected in control experiments performed on lysates from postnatal mouse frontal cortex.
While these results certainly suggests that α4 and δ are expressed at lower levels than the α1, α3
and α5 subunits also studied in the western blotting experiments, the specificity and sensitivity
of the antibodies used and/or the preparation of the lysate from the neuronal culture could
also be contributing factors to the lack of detected bands for α4 and δ. Thus, the expression of
α4 and δ in the primary neurons were investigated further by RT-qPCR analysis, where the
respective expression levels of the mRNAs of the three β subunits also were determined. The
α4 and δ transcripts were detected in similar levels in the neurons (Fig 1E). However, the
expression levels of mRNAs for both subunits were substantially lower than the levels deter-
mined for the β1, β2 and β3 transcripts, with the levels of α4 and δ mRNAs being 11-, 1.7- and
11-fold and 9.3-, 1.5- and 9.2-fold lower, respectively, than those determined for β1, β2 and β3
(Fig 1E). For comparison, we also performed RT-qPCR analysis of postnatal mouse frontal
cortex. It is important to stress that absolute mRNA levels of proteins in the primary neurons
and in mouse frontal cortex are not directly comparable since the cellular composition of the
tissue and the culture are very different, and thus the mRNA levels of α4, β1-β3 and δ in the tis-
sue were as expected higher than the levels for the subunits in the primary neurons (Fig 1E).
Interestingly, however, the relative expression of the five subunits followed roughly same pat-
tern as seen in postnatal mouse frontal cortex, with a somewhat higher relative expression of δ
compared being the major difference (Fig 1E). In conclusion, the expression levels of α4 and δ
mRNAs in the primary neurons determined in the RT-qPCR analysis are sufficiently high to
suggest that the subunits could be expressed at protein level, and importantly the lower expres-
sion levels of these two subunits compared to those of other α subunits and of the β subunits
are in good agreement with the relative subunit expression levels in mouse frontal cortex. On
the other hand, the apparently low expression levels of δ-GABAARs in the primary neurons
used for the MEA recordings naturally raises the question, to which extent pharmacological
modulation of δ-GABAAR signalling is capable of influencing network activity, which will be
address further in the Discussion section.
MEA recordings and multi-parametric analysis of network activity. Spike rate is a parameter
describing general activity but this is not nessecarily the most descriptive parameter that can
be derived from MEA recordings. Thus, multi-parametric data analysis has in recent years
gained more attention as spatio-temporal recordings of action potentials from numerous indi-
vidual neurons offer additional insights into network functionality [17]. In addition to infor-
mation about the effects of a substance on spike rates and burst rates, information about its
impact on synchronicity, regularity of oscillation, burst structure and network connectivity
can also be derived by this analysis (Fig 2A). In particular burst structure characteristics are
essential features for describing the changes in the activity patterns induced by a substance.
Moreover, analysis of synchronicity is possible with a high resolution in time and per neuron,
and oscillatory behaviour can be measured as the rates of action potentials occurring with peri-
odicity over time (Fig 2A). Both synchronicity and oscillation are important characteristic phe-
nomena in neuronal network activity in vitro [17, 20, 22]. We observed this synchronized and
regular activitiy pattern also in vivo using multi-electrode intra-cortical recordings which
underlines the physiological relevance of the in vitro patterns (in-house data).
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The principles of the MEA recordings, the experimental set-up, the raw data obtained from
the recordings, and the subsequent multi-parametric data analysis performed in this study are
illustrated in Fig 2A. The 204 activity-describing parameters calculated based on the spike
trains from the multichannel recordings are divided into four categories (Fig 2A). “General
Activity” parameters are global network activity descriptors (e.g. spike rate, burst rate, % of
spikes in bursts and burst period), whereas “Burst Structure” parameters describe the internal
structure of spikes within a high-frequency spiking phase (e.g. spike frequency in bursts, spike
rate in bursts, spike density) as well as the overall burst structure (e.g. the duration, area, pla-
teau of the burst). “Oscillatory Behavior” parameters are the standard deviations associated
with main General Activity and Burst Structure parameters, and these parameters are thus
descriptors of the regularity of bursting events within experimental episodes, with higher val-
ues indicating less regular general activity or less regular burst structure. Finally, the “Synchro-
nicity” parameters include those representing the coefficient of variation over the network.
Thus, the Synchronicity CVnet values are reflecting the level of synchronization amongst the
neurons, i.e. the degree of variation for the respective General Activity or Burst Structure
parameter between individual units in a network. The lower the CVnet, the higher the syn-
chronicity among neurons and vice versa. The 40 activity parameters shown in heat maps in
Figs 3–10 represent a wide view on concentration-dependent effects of agents and thus the
phenotypic fingerprint which is unique to every compound but similar between compounds
with same modes of action. Full names and definitions of the 40 parameters are given in S1
Table.
Under optimal culture conditions the MEA cultures display stable activity levels for several
hours with only a few parameters exhibiting changed properties over time (Fig 2B). Moreover,
DMSO mediates either no significant effects or negligible effects on all activity parameters
when applied at assay concentrations up to 0.1%. This stability allows measurements of the
effects induced by cumulatively increasing concentrations of a drug on the same network in
recordings over a time period of 8–9 h and the subsequent normalization the all activity
parameter data for a specific drug concentration to the intrinsic native activity recorded (con-
trol). In conclusion, robust data describes the complete concentration-response relationships
for all activity parameters for the drugs.
Because of the holistic nature of the information extractable from MEA recordings on neu-
ronal networks, there are aspects of GABAAR signaling and its contributions to overall
GABAergic transmission that may be addressed in slice and patch-clamp recordings at neu-
rons but not in these recordings. In the present study, application of cumulatively increasing
concentrations of the different GABAergic agonists and PAMs did not lead to visible desensiti-
zation of the induced changes in the activity parameters over time. That is not to say that expo-
sure of the networks to these drugs (especially at high concentrations) does not induce
Fig 2. Multiparametric analysis of cortical neuron network activity. A. Recording setup and multiparametric analysis of cortical neuron network
activity. i. Culture of neuronal networks on MEA neurochips. Two-well MEAs with 2x32 electrodes were used to acquire extra-cellular action potentials
called spikes. ii. Examples of raw data from MEA recordings at cortical neurons. Wave forms from different neurons are separated yielding high-
quality spike train data of single neurons in a network. iii. Spike raster plots of native cortical activity (control) and cortical activity after acute treatment
with 300 nM diazepam or 5 μM picrotoxin. The augmentation and inhibition of GABAAR signaling mediated by the two respective drugs is observed to
reduce and increase overall spiking and bursting activity, respectively. iv. Multiparametric analysis of MEA data. Top: Raw data (magnified detail from a
spike raster plot, iii) with the origin of the four defined categories of activity parameters indicated. Bottom: Scheme of two simplified bursts outlining
some of the major General Activity [burst inter burst interval (IBI) and burst period] and Burst Structure [burst duration, burst plateau, burst amplitude,
burst inter-spike interval (ISI) and burst area] parameters extractable from the recordings. B. Stability of spike rate and burst rate of cortical networks
recorded over 19 h in the absence of drug. C. Exemplification of the data presention in Figs 3–10. The effects of cumulatively increasing concentrations
of the GABAAR PAM methaqualone on network activity parameters are given as concentration-response curve for the “Spike Rate” parameter (top)
and as a heat map depicting statistically significant changes in several activity parameters relative to native activity (the activity at time point 0, 100%,
Student’s paired t-test, p0.05) (bottom). The methaqualone data has been published previously [22].
https://doi.org/10.1371/journal.pone.0186147.g002
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desensitization of individual GABAARs in the neurons. However, this ongoing desensitization
(and subsequent resensitization) of individual receptors in the neurons either does not mani-
fest itself significantly in the measured read-outs in the recordings or this desensitization may
actually be imbedded in the observed changes in the various activity parameters induced by
the drugs. Furthermore, it is also not possible to differentiate between the respective contribu-
tions of presynaptic and postsynaptic GABAARs to the total effects at network activity induced
by a specific drug in the MEA recordings. On the other hand, provided that activity patterns in
the pre-frontal cortex cultures used for the MEA recordings to a reasonable degree are reflec-
tive of cortical activity patterns in vivo, we propose that the drug-induced network activity
changes in this system can offer interesting information about other aspects of GABAAR-
mediated functions in an in vivo setting.
Muscimol and baclofen
Initially the effects on cortical network activity produced by selective activation of GABAARs
or GABABRs were studied by applications of muscimol and baclofen, respectively. Muscimol
is a pan-GABAAR agonist displaying full agonism and EC50 values in the high nanomolar/low
micromolar range at various receptor subtypes expressed in oocytes or mammalian cells [40–
42], and baclofen is a selective full GABABR agonist exhibiting low micromolar EC50 values at
the recombinant GABABRs [43–45]. In the MEA recordings, muscimol and baclofen were
applied at the networks at concentrations up to 3 μM and 10 μM, respectively, and activity
changes induced by the two drugs must thus be assumed to arise from substantial (if not maxi-
mal) degrees of activation of GABAARs and GABABRs, respectively. Importantly, the concen-
tration-response relationships exhibited by muscimol (EC50 ~100 nM) and baclofen (EC50
~1 μM) at major General Activity parameters such as “Spike Rate” and “Burst Rate” were in
concordance with the reported potencies for the two agonists at their respective recombinant
receptors. Muscimol and baclofen mediated very similar changes in the General Activity
parameters, with both drugs inducing overall suppression of network activity in the form of
decreased spike and burst rates and increased burst periods and inter-burst intervals (Fig 3).
In contrast, the two drugs modulated several Burst Structure parameters differently, with mus-
cimol decreasing burst durations and amplitudes and baclofen inducing the opposite effects
(Fig 3). Moreover, whereas GABAAR activation mainly decreased the variation of General
Activity and Burst Structure parameters between different bursts, GABABR activation had
more subtle impact on this variation and in some cases even increased it (Oscillatory Behavior
parameters, Fig 3). Thus, the changes in neuronal network activity resulting from stimulation
of GABAAR and GABABR signalling were phenotypically distinct. In the subsequent experi-
ments we probed the contributions of different receptor populations to the GABAAR-medi-
ated effects.
Positive allosteric modulators (PAMs) of αβγGABAARs
To assess the network effects arising from selective augmentation of synaptic αβγ GABAAR
signalling, the benzodiazepines diazepam, flunitrazepam and clonazepam and the benzodiaze-
pine-site PAM zolpidem were characterized at the neuron cultures. All these four PAMs act
through the high-affinity benzodiazepine binding sites formed at the extracellular α(+)/γ(–)
Fig 3. Changes in cortical network activity induced by 7–10 cumulatively increasing concentrations of the GABAAR agonist muscimol
and the GABABR agonist baclofen. The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no
drug, 100%) (Student’s paired t-test, p0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as
mean ± S.E.M. relative to native activity (no drug, 100%).
https://doi.org/10.1371/journal.pone.0186147.g003
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subunit interface in α1,2,3,5βγ GABAARs, and in the concentration ranges used in the MEA
recordings the modulators will act exclusively at these receptors without affecting other sub-
types. Diazepam, flunitrazepam and clonazepam are fairly non-selective PAMs, and the net-
work effects mediated by these modulators must thus be assumed to arise from modulation of
all α1,2,3,5βγ receptors [46–49]. In contrast, zolpidem is α1-preferring PAM exhibiting EC50 val-
ues of ~100 nM at α1βγ receptors, ~10-fold higher EC50 values at α2βγ and α3βγ receptors and
negligible activity at α5βγ receptors in heterologous expression systems [48, 50–52]. Thus, the
network effects mediated by low concentrations of zolpidem must predominantly be ascribed
to α1βγ receptors, whereas α2βγ and α3βγ subtypes are likely to contribute the effects observed
at higher concentrations of the modulator.
All in all, diazepam, flunitrazepam, clonazepam and zolpidem induced similar effects at the
neuronal networks in the MEA recordings (Fig 4). However, the degrees of modulation
exerted by the four PAMs differed somewhat at some of the activity parameters, most notably
flunitrazepam exerted significant effects at more Burst Structure parameters than the other
PAMs. The changes in the various activity parameters brought on by the four PAMs were,
with a few exceptions, in the same qualitative directions as those induced by muscimol. Inter-
estingly, however, sub-saturating concentrations of muscimol induced considerably more pro-
nounced effects on major General Activity parameters such as “Spike Rate” and “Burst Rate”
than saturating concentrations of the PAMs (Figs 3 and 4). This difference could be rooted in
this pan-GABAAR agonist targeting a broader spectrum of GABAAR subtypes than the benzo-
diazepine-site PAMs. Alternatively, since the PAMs are dependent on concomitant agonist
binding to the receptors to mediate their effects, the maximal degrees of modulation induced
by them in these recordings could also be limited by the endogenous concentration of GABA
in the assay.
In concordance with their somewhat higher potencies as PAMs at recombinant α1,2,3,5βγ
receptors, flunitrazepam and clonazepam were observed to be slightly more potent than diaze-
pam at most General Activity and Burst Structure parameters. Interestingly, the degrees of
modulation induced by 100 nM zolpidem and 100 nM diazepam at the various activity param-
eters were largely comparable (Fig 4). Since diazepam and zolpidem are essentially equipotent
PAMs at α1βγ receptors expressed in Xenopus oocytes (EC50 values ~100 nM) [47, 48, 50, 51],
the two modulators must be assumed to exert comparable degrees of α1βγ receptor modula-
tion at this concentration, whereas diazepam (100 nM) in contrast to zolpidem (100 nM) also
will mediate substantial modulation of α2,3,5βγ receptors. Thus, the comparable effects of the
two modulators is likely to be a reflection of the fact that α1βγ receptors (including α1αxβγ
receptors comprising an α1
(+)/γ(–) subunit interface) are the major synaptic GABAAR subtypes
in cortical neurons [2].
THIP and Thio-THIP
The orthosteric GABAAR ligands THIP and Thio-THIP both exhibit functional selectivity for
δ-GABAARs over other receptor subtypes. While THIP is an agonist at a wide range of
GABAARs, it exhibits substantially higher maximal responses (relative to GABA) at δ-
GABAARs than at αβγ receptors [42, 53–55]. More importantly, THIP is also a more potent
agonist at α4βδ receptors than at αβγ and αβ receptors, and this selectivity for δ-GABAARs
Fig 4. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of the αβγGABAAR PAMs
diazepam, flunitrazepam, clonazepam and zolpidem. The heat maps present statistically significant changes in 40 activity parameters
relative to native activity (no drug, 100%) (Student’s paired t-test, p0.05). The concentration-response relationships for the drugs at 10
selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%).
https://doi.org/10.1371/journal.pone.0186147.g004
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Fig 5. Changes in cortical network activity induced by 7–9 cumulatively increasing concentrations of the functionally selective δ-GABAAR
agonists THIP and Thio-THIP. The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%)
(Student’s paired t-test, p0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M.
relative to native activity (no drug, 100%).
https://doi.org/10.1371/journal.pone.0186147.g005
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Fig 6. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of the δ-GABAAR-selective modulators DS1
and DS2. The heat maps present statistically significant changes in 40 activity parameters relative to native activity (no drug, 100%) (Student’s paired t-test,
p0.05). The concentration-response relationships for the drugs at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no
drug, 100%).
https://doi.org/10.1371/journal.pone.0186147.g006
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within a certain concentration range has made THIP the prototypic pharmacological tool for
these receptors [42, 53–56]. The close structurally related analog Thio-THIP is a functionally
subtype-selective α4βδ GABAAR ligand, as it acts as a partial agonist at α4β1δ and α4β3δ recep-
tors and exhibits negligible agonist activity at α4β2δ and αβγ GABAARs [57].
Both THIP and Thio-THIP induced significant changes in cortical network activity in a
concentration-dependent manner (Fig 5). THIP exhibited EC50 values in the 10–30 μM range
at the majority of the General Activity parameters, and applications of 3 μM or 10 μM THIP
produced significant effects at most of the activity parameters (Fig 5). In electrophysiological
recordings at recombinant GABAARs expressed in Xenopus oocytes or mammalian cells,
THIP has been found to induce α4βδ receptor signaling without concomittant activation of
αβγ receptors within a concentration range spanning from high-nanomolar concentrations to
approximately 10 μM [42, 54, 55, 57], which indicate that the significant network effects
induced by THIP at 3 and 10 μM concentrations could be mediated predominantly through δ-
GABAARs. Conversely, in slice recordings high-nanomolar concentrations of THIP have been
shown to induce robust tonic currents in neurons expressing α4βδ GABAARs as major extrasy-
naptic receptors [57–60], suggesting that significant network effects perhaps could have been
expected to arise from lower THIP concentrations than 3/10 μM. Thus, if one were to go by
the ability of THIP to induce tonic currents at high-nanomolar concentrations the fact that
concentrations of 3 μM and higher were required to induce signficant network effects could be
interpreted either as lack of expression of δ-GABAARs in the neurons or as a reflection of neg-
ligible contributions of δ-GABAAR signaling to network activity. On the other hand, even
though the low degree of δ-GABAAR occupancy and activation seen at high-nanomolar con-
centrations of THIP is able to tonic currents there does not necessarily have to be a 1:1 correla-
tion between its effects at these concentrations and the THIP concentrations capable of giving
rise to significant changes in the activity parameters in the MEA recordings. In conclusion,
although the observation that THIP first induces significant networks effects at 3/10 μM con-
centrations where the agonist is known to begin to activate αβγ and other GABAARs as well
could be taken as an indication that its network effects could arise from these receptors rather
than from δ-GABAARs, it could also mean that the δ-GABAAR-mediated effects on network
activity requires a higher degree of receptor occupancy by THIP. In the latter case, the net-
works effects induced by THIP (3/10 μM) could be mediated through both αβγ and δ-
GABAARs.
Whereas THIP could be tested at the networks at concentrations up to 3 mM, application
of Thio-THIP at concentrations of 300 μM and higher resulted in neurotoxic effects. Thus,
Thio-THIP was only tested at concentrations up to 100 μM, where these effects were not
observed. Within this concentration-range Thio-THIP mediated changes in substantially
fewer network activity parameters than THIP, and significant effects were mostly seen at con-
centrations of 30 μM and 100 μM (Fig 5). In view of its negligible activity at recombinant αβγ
GABAARs at concentrations up to 100 μM, the effects of Thio-THIP on network activity most
likely arise from its agonism at δ-GABAARs, and the fact that significant effects typically only
arises from compound concentrations of 30 μM or 100 μM seems to concord with its potency
Fig 7. Changes in cortical network activity induced by 8 cumulatively increasing concentrations of DS2 in the absence and in the
presence of 3 μM or 15 μM THIP. The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity
parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p0.05). The concentration-response relationships for the drug
combinations at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the right
of the vertical hatched line present statistically significant changes in the 40 activity parameters between the activity induced by a specific DS2
concentration co-applied with 3 μM or 15 μM THIP relative to the activity induced by THIP on its own (3 μM or 15 μM, respectively) (100%)
(Student’s paired t-test, p0.05).
https://doi.org/10.1371/journal.pone.0186147.g007
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Fig 8. Changes in cortical network activity induced by 7–8 cumulatively increasing concentrations of THIP in the absence and in the presence of
300 nM, 1 μM or 3 μM DS2. The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity parameters relative to
native activity (no drug, 100%) (Student’s paired t-test, p0.05). The concentration-response relationships for the drug combinations at 10 selected activity
parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the right of the vertical hatched line present statistically
significant changes in the 40 activity parameters between the activity induced by a specific THIP concentration co-applied with 300 nM, 1 μM or 3 μM DS2
relative to the activity induced by that specific THIP concentration on its own (100%) (Student’s paired t-test, p0.05).
https://doi.org/10.1371/journal.pone.0186147.g008
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as a α4βδ receptor agonist. Moreover, judging from its functional selectivity profile at the three
recombinant α4βδ subtypes these effects are likely to be mediated through α4β1δ and/or α4β3δ
receptors [57].
DS1 and DS2
Next the close structurally related allosteric ligands DS1 and DS2 were tested at the cortical
networks. DS1 and DS2 have been reported to be selective modulators of δ-GABAAR (in par-
ticular α4βδ and α6βδ) over α1,2,3,5β2γ2 and α4β3 receptors expressed in oocytes and mamma-
lian cells [61, 62]. DS1 exhibits pronounced intrinsic activity and thus acts both as an allosteric
agonist and a PAM (ago-PAM) at recombinant α4β3δ receptors, whereas DS2 has been
reported to be a pure PAM at these receptors [61, 62]. Importantly, however, both compounds
modulate αβγ receptors in the same concentration range as δ-GABAARs, and the proposed δ-
GABAAR selectivity of these compounds are thus rooted in the dramatically higher efficacies
exhibited by them as modulators of these receptors than at the αβγ receptors [54].
In the MEA recordings DS1 and DS2 were both applied in concentration ranges that cover
most of their effective concentration-response relationships at recombinant α4β3δ GABAARs
[54, 61, 62]. Interestingly, DS2 either mediated very subtle effects or no significant effects at
the various activity parameters at concentrations up to 5 μM (the highest concentration tested
due to restrictions in terms of the maximum assay concentration of DMSO), whereas DS1
induced pronounced effects in a concentration-dependent manner at the majority of parame-
ters in all four classifications (Fig 6). Importantly, significant effects were observed from appli-
cations of even low nanomolar DS1 concentrations, and the ago-PAM exhibited EC50 values
in the 100–300 nM range at several of the major General Activity and Burst Structure parame-
ters, which is in agreement with its reported potency at recombinant α4βδ receptors [54, 61].
The DS1-induced changes in the activity parameters were all in the same directions as those
mediated by THIP (3/10 μM) and by Thio-THIP (Fig 5), and the changes were also phenotypi-
cally similar to those produced by the benzodiazepine-site PAMs (Fig 4). Assuming that the
network effects mediated by THIP (3/10 μM) and Thio-THIP predominantly can be ascribed
to δ-GABAAR activation, the substantially more pronounced changes in the activity parame-
ters mediated by DS1 could be ascribed to the higher efficacy of this ago-PAM at δ-GABAARs
than THIP (3/10 μM) and the partial agonist Thio-THIP [42, 54, 55, 57, 61].
We found the dramatically different efficacies of DS1 and DS2 in the MEA recordings inter-
esting. The DS2 sample used in the MEA recordings was found to exhibit robust PAM activity
at recombinant α4β3δ GABAARs expressed in Xenopus oocytes, and thus the negligible effects
of the PAM at cortical network activity could not be ascribed to lack of δ-GABAAR activity in
this specific sample. Moreover, as outlined above the effects mediated by DS1, Thio-THIP and,
to some extent, THIP suggest that augmentation of δ-GABAAR signaling is impact network
activity. Thus, we speculated that the negligible effects mediated by DS2 could be rooted in
GABA concentrations surrounding extrasynaptic δ-GABAARs in the neurons being too low to
enable the PAM to mediate its effects. To investigate this possibility, we studied the network
effects induced by DS2 in the presence of a trace concentration of THIP. Co-application of
Fig 9. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of diazepam in the absence and in
the presence of 30 nM DS1. The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity
parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p0.05). The concentration-response relationships for the drug
combinations at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the
right of the vertical hatched line present statistically significant changes in the 40 activity parameters between the activity induced by a specific
diazepam concentration co-applied with 30 nM DS1 relative to the activity induced by 30 nM DS1 on its own (100%) or relative to the activity
induced by that specific diazepam concentration on its own (100%) (Student’s paired t-test, p0.05).
https://doi.org/10.1371/journal.pone.0186147.g009
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DS2 (0.1 nM-5 μM) with 3 μM THIP produced very subtle changes in the activity parameters,
both when compared to the activity recorded in native cells and to the activity arising from the
initial application of 3 μM THIP (Fig 7). Even when DS2 (0.1 nM-5 μM) was co-applied with
15 μM THIP, a concentration of the agonist that on its own induced significant changes in sev-
eral activity parameters and thus must be assumed to exert robust δ-GABAAR activation, the
effects induced by the PAM were subtle albeit more substantial than those induced in the pres-
ence of 3 μM THIP (Fig 7). Interestingly, DS2 predominantly augmented the 15 μM THIP-
mediated effects at Burst Structure parameters, whereas the General Activity parameters were
largely unaffected by the presence of the modulator (Fig 7).
In reverse experiments, the concentration-response relationships for THIP at the network
activity parameters were determined in the presence of 300 nM, 1 μM or 3 μM DS2, three con-
centrations that cover most of the effective concentration range of DS2 (~EC30-EC90) at
recombinant α4β3δ GABAARs [54, 61, 62]. The presence of DS2 during these recordings only
impacted the concentration-response relationships exhibited by THIP slightly, the most sub-
stantial modulation being observed at lowest PAM concentration (Fig 8). The presence of 300
nM DS2 in the assay right-shifted the concentration-response relationships displayed by THIP
or reduced its efficacy at several General Activity and Burst Structure parameters (Fig 8). Albeit
this modulation was subtle this DS2 concentration thus seemed to counteract the network
effects arising from THIP-mediated δ-GABAAR modulation, whereas the presence of higher
concentrations of the modulator (1 μM and 3 μM) generally were without effect (Fig 8).
Diazepam and DS1 combinations
Having studied the changes in network activity mediated by selective modulators of αβγ
GABAARs and δ-GABAARs, we next set out to investigate the putative functional interplay
between the two receptor classes in the neurons, i.e. to which extent concomittant δ-GABAAR
signalling would impact the network changes mediated by αβγ GABAARs and vice versa. DS1
and diazepam were applied as selective mediators of signalling through these two receptor clas-
ses in the recordings, where the concentration-response relationships for one modulator were
determined at the networks in the concomitant presence of a fixed low concentration of the
other. Concentrations of 30 nM DS1 and 50 nM diazepam were used for the recordings, since
these concentrations of the respective drugs produced small but significant changes in the
majority of activity parameters in the original recordings (Figs 4 and 6).
The network activity changes induced by diazepam (1 nM-10 μM) in the presence of 30 nM
DS1 were all characterized by the same directions as those induced by the benzodiazepine on
its own (Fig 9). In these recordings, application of 30 nM DS1 on its own induced more mod-
est effects on the activity parameters than expected based on its concentration-response rela-
tionships in the original DS1 recordings (Fig 6). Nevertheless, when co-applied with this trace
concentration of DS1 diazepam was strikingly less efficacious at the networks than when
applied on its own. In fact, the concentration-response relationships exhibited by the “diaze-
pam (30 nM DS1)” combination at numerous activity parameters (including major General
Activity and Burst Structure parameters such as “Spike rate”, “Burst rate”, “Burst duration” and
Fig 10. Changes in cortical network activity induced by 8–9 cumulatively increasing concentrations of DS1 in the absence and in the
presence of 50 nM diazepam. The heat maps to the left of the vertical hatched line present statistically significant changes in 40 activity
parameters relative to native activity (no drug, 100%) (Student’s paired t-test, p0.05). The concentration-response relationships for the drug
combinations at 10 selected activity parameters are given as mean ± S.E.M. relative to native activity (no drug, 100%). The heat maps to the
right of the vertical hatched line present statistically significant changes in the 60 activity parameters between the activity induced by a specific
DS1 concentration co-applied with 50 nM diazepam relative to the activity induced by 50 nM diazepam on its own (100%) or relative to the
activity induced by that specific DS1 concentration on its own (100%) (Student’s paired t-test, p0.05).
https://doi.org/10.1371/journal.pone.0186147.g010
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“Burst amplitude”) were dramatically right-shifted compared to those evoked by diazepam on
its own, in some cases up to ~30-fold (Fig 9). Thus, the concomittant presence of this low DS1
concentration appeared to decrease the sensitivity of the neurons to the diazepam-mediated
αβγ GABAAR signalling.
In another experiment the roles of the two modulators were reversed, and DS1 (0.1 nM-
3 μM) was co-applied with 50 nM diazepam at the networks (Fig 10). In agreement with the
original diazepam recordings (Fig 4), application of 50 nM diazepam mediated significant
effects on the majority of activity parameters, inducing responses constituting up to ~30% of
the responses induced by saturating diazepam concentrations (Fig 10). The network activity
changes arising from DS1 in the presence of 50 nM diazepam were all characterized by the
same qualitatively directions as those induced by DS1 on its own. Moreover, when the isolated
effects mediated by 50 nM diazepam on the networks were taken into account, the concentra-
tion-response relationships exhibited by the “DS1 (50 nM diazepam)” combination at the
activity parameters either did not differ signifiantly or were only slightly different (mostly
right-shifted) compared to those displayed by DS1 on its own (Fig 10). Thus, in contrast to the
observation made in the reverse experiment, a moderate level of stimulation of αβγ GABAARs
thus did not seem to affect the network effects mediated by DS1 in this experimental set-up
substantially.
Discussion
In the present study the effects of various pharmacological tools characterized by different
modulatory properties and selectivity profiles at GABAARs on cortical neuronal network activ-
ity were characterized investigated by use of MEA recordings and multiparametric data analy-
sis. We report that selective augmentation of GABAAR and GABABR signaling by the pan-
agonists muscimol and baclofen, respective, mediate phenotypically distinct changes in net-
work activity, and that the networks effects induced by wide range of GABAAR modulators
with different subtype-selectivity profiles largely were in the same qualitative directions, albeit
with some interesting exceptions. Thus, benzodiazepine-site PAMs selective for αβγ GABAARs
as well as the reported δ-GABAAR-selective agents DS1 and Thio-THIP induced robust
changes in a broad range of activity parameters. Interestingly, the efficacious modulation of
network activity mediated by the ago-PAM DS1 was contrasted by the negligible effects exhib-
ited by its close structural analog DS2, another reported δ-GABAAR-selective PAM, at the neu-
rons. Finally, in studies of the putative functional interplay between αβγ GABAARs and δ-
GABAAR, co-administration of diazepam with a low but effective concentration of DS1 was
found to decrease the apparent potency of the bezodiazepine at numerous activity parameters,
whereas low levels of concomittant αβγ GABAAR stimulation had little impact on the DS1-in-
duced network effects.
Interpretations made in any study probing native GABAAR signaling with pharmacological
tools are obviously reliant on the reported functional properties of these at recombinant
receptors being accurate and as detailed as possible. Furthermore, although functionalities
of ligands determined at recombinant GABAARs usually are assumed to be mirrored at the
native receptors, this may not always be the case. This is particular true for the α4βδ GABAARs
that assemble into different functional receptor stoichiometries and arrangements in heterolo-
gous expression systems that may not all exist in vivo [63–67]. Thus, even though the αβγ
GABAAR selectivity of the benzodiazepine-site PAMs [46–52], the efficacy-based functional
selectivity of DS1 and DS2 as δ-GABAAR modulators [54, 61, 62], and the functional δ-
GABAAR selectivity of THIP and Thio-THIP [42, 56, 57] are well-founded in the literature,
such considerations are also valid for this study. It is also important to stress that while α1,2,3βγ
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GABAARs and δ-GABAARs (mainly α4βδ) are the predominant synaptic and extrasynaptic
receptors in cortical neurons, other subtypes are likely to be expressed at both sites in these
neurons and to contribute to phasic and tonic inhibition as well, analogously to what has been
demonstrated in other brain regions [11, 13, 68–70]. The reported expression of extrasynaptic
α5βγ receptors in layer 5 cortical neurons [71] is particular relevant, since the networks effects
induced by diazepam, flunitrazepam and clonazepam thus potentially could comprise a com-
ponent arising from activation of these receptors. As outlined in Results, however, the similar-
ity of the networks effects mediated by the benzodiazepines to those of zolpidem, a PAM with
negligible α5βγ activity, strongly suggests that the effects predominantly are attributable to acti-
vation of α1,2,3βγ receptors (Fig 4). Thus, while keeping the heterogeneity of native GABAARs
and the other aspects outlined above in mind, we propose that the GABAAR ligands applied in
this study relatively specifically delineate the networks effects arising from augmentation of the
signalling of αβγ GABAARs and δ-GABAARs.
Another general concern in studies of GABAAR-mediated effects in neuronal cultures is
obviously to which extent the relative distribution and the expression levels of various receptor
subtypes in the cultures mirror those in native tissues and to which degree effects observed for
various pharmacology tools here can be extrapolated to the in vivo situtation. As evidenced by
the substantial expression levels detected for the α1, α3 and β1-β3 subunits in neuronal culture
lysates and by the robust network activity changes mediated by four benzodiazepine-site
PAMs in concentration ranges in good agreement with their modulatory potencies at recombi-
nant αβγ GABAARs (Figs 1 and 4), there is little doubt that αβγ GABAARs are expressed in the
primary neurons and are of major importance for the level of spontaneous activity in these
networks. However, when it comes the δ-GABAARs, the data presented in this study is admit-
tedly more ambiguous and open to interpretation. Even through the significantly lower
expression levels of α4 and δ subunits compared to β1-β3 in the primary neurons are in concor-
dance with the relative expression of these subunits in postnatal mouse frontal cortex (Fig 1E),
it is reasonable to question whether δ-GABAARs expressed at such low levels would be able to
exert substantial effects on network activity. Unfortunately, the network effects mediated by
the four drugs applied in this study to elucidate the importance of these δ-GABAARs are also
quite ambiguous. The fact that DS1 and Thio-THIP mediate robust modulation of the major-
ity of activity parameters and at these exhibit concentration-response relationships that con-
cord with their respective potencies at recombinant δ-GABAARs seem to support the notion
of these receptors being important for spontaneous activity in the networks (Figs 5 and 6). As
outlined in detail in the Results section, the concentration-response relationship exhibited by
THIP in its modulation of network activity can both be argued to substantiate and to disprove
an involvement of δ-GABAARs, and as such the data for this drug does not offer clarity on the
issue. Finally, the negligible modulation of network activity mediated by the δ-selective PAM
DS2, both when applied on its own and with THIP, conversely suggests that the contributions
of δ-GABAARs to network activity changes could be minute (Figs 6–8). However, in contrast
to its potent and highly efficacious modulation of recombinant α4βδ GABAARs, DS2 is not a
particular potent inducer of tonic inhibition through native α4βδ receptors in murine thalamic
ventrobasal neurons, where it only elicits significant tonic currents at a concentration of 3 μM
[61, 62]. Thus, the fact that DS2 in this study only was tested at concentrations up to 5 μM
could perhaps explain its modest effects on network activity. In conclusion, we favor an inter-
pretation of these data where the observed effects of DS1, Thio-THIP and, to some extent,
THIP (3/10 μM) on network activity are mediated predominantly through δ-GABAARs.
Although we can not completely exclude the possibility that the low expression levels of δ-
GABAARs in the neurons could mean that these receptors do not contribute significantly to
the observed network activity changes, any alternative explanation would require both DS1
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and Thio-THIP to mediate their robust network effects through other targets than δ-
GABAARs, which we find a more unlikely scenario.
The dramatically different modulation of network activity mediated by the close structural
analogs DS1 and DS2 in the MEA recordings is truly striking. As mention above, we propose
that the DS1-mediated effects are arising from δ-GABAAR modulation, and the effective con-
centration ranges exhibited by DS1 at the various activity parameters are certainly in good
agreement with the reported potencies for it as an ago-PAM at recombinant α4βδ GABAARs
(Fig 6) [54, 61]. To our knowledge, there are no published studies of the modulation exerted
by DS1 at native δ-GABAARs, and thus it remains to be seen whether DS1 analogously to DS2
displays different modulatory potency in its induction of tonic currents in slice recordings
than at recombinant δ-GABAARs. However, considering that DS1 is a ~10-fold more potent
PAM at recombinant α4βδ GABAARs than DS2 and, in contrast to DS2, also exhibits pro-
nounced intrinsic agonist activity at the receptors [54, 61], DS1 would be expected to be a
more potent and efficacious potentiator of native extrasynaptic δ-GABAARs than DS2. That
being said, the dramatically different effects induced by DS1 and DS2 on cortical network
activity can not be rationalized solely be these differences in the modulatory properties of the
compounds at the recombinant receptors, and thus it could be interesting to further address
the mechanism(s) underlying DS1-mediated modulation of neuoronal network activity in
future studies.
The putative functional interplay between αβγ GABAARs and δ-GABAARs in the cortical
networks was probed in this study using diazepam and DS1 as pharmacological tools for the
respective receptor classes. Considering the above-mentioned inconclusiveness of δ-GABAAR
expression and/or the importance of these receptors for the network activity in these cultures,
any interpretations of observations made in these experiments inevitably will depend heavily
on whether the network activity changes induced by DS1 are indeed mediated though δ-
GABAARs or whether they arise from other yet unidentified activities of the drug. In the fol-
lowing, the DS1-mediated effects will be assumed to arise predominantly from δ-GABAAR
modulation, analogously to the selective potentiation of αβγ GABAAR signaling exerted by
diazepam.
Whereas a low degree of δ-GABAAR activation by DS1 was observed to reduce the sensitiv-
ity of the cortical networks to αβγ GABAAR signalling substantially, moderate activation of αβγ
GABAARs did not seem to impact δ-GABAAR-mediated activity changes substantially (Figs 9
and 10). The mechanisms underlying the phenomenon of homeostatic plasticity of inhibitory
neuron excitability and output are poorly understood, including how and to which extent syn-
aptic and extrasynaptic GABAARs interact with each other to balance tonic and phasic inhibi-
tion [14]. In previous studies overexpression of α6βδ or α5βγ2 receptors at extrasynaptic sites in
hippocampal neurons have not only been shown to result in increased tonic currents but also in
significantly decreased synaptic GABAAR responses [72, 73]. In one of these studies, the reduc-
tion in synaptic transmission was ascribed to competition between extrasynaptic and synaptic
receptors for a limited number of receptor slots at the neuron surface [73]. While this may be a
plausible explanation for the observed effects in neurons with manipulated receptor expression
levels, it can not be extended to this study where the putative functional interplay between the
two receptor groups were assessed by pharmacological tools at neurons characterized by endog-
enous receptor expression levels. In this set-up, the observed differences between the concentra-
tion-response relationships for one modulator in the absence and in the presence of another
modulator reflect the acute effects arising from low levels of concomitant signalling of the other
receptor group. Thus, although dynamic regulation of cell surface expression levels of receptors
in these neurons very well could be an underlying cause of the observed effects, other mecha-
nisms could be involved as well, just as the homeostatic plasticity of inhibitory synapses could
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be rooted in multiple molecular and cellular mechanisms. For example, the phosphorylation
and dephosphorylation of Ser, Thr and Tyr residues in intracellular GABAAR subunit regions
mediated by various kinases and phosphatases has been proposed to constitute a dynamic bal-
ance modulating cell surface trafficking of GABAARs as well the functional properties of the
receptors [14, 74]. Not having investigated these putative mechanisms in this study, we will
refrain from further speculations about them.
Conclusion
This work should be considered complementary to the numerous studies of synaptic αβγ
GABAARs and extrasynaptic δ-GABAARs in neuronal cultures or brain slices by means of con-
ventional electrophysiology. The network effects arising from signalling mediated by the two
receptor groups were probed with several selective pharmacological tools, and the concentra-
tion-response relationships exhibited by the modulators were generally in good agreement
with their functional properties at their respective recombinant target receptors. Hence, we
propose that the multi-parametric analysis of MEA data allows for a detailed description of
network activity changes in the cortical networks exhibited by phenotypic fingerprints deter-
mined for various GABAAR modulators and that this holistic approach to the study of these
receptors offer interesting insights into the respective roles of αβγ GABAARs and δ-GABAARs
and the putative functional interplay between them in the neurons.
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